荣昌生物
(688331)
| 流通市值：210.90亿 | | | 总市值：729.93亿 |
| 流通股本：1.63亿 | | | 总股本：5.64亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 656,214,449.91 | 3,251,051,061.93 | 1,719,833,029.78 | 1,097,953,438.31 |
| 营业收入 | 656,214,449.91 | 3,251,051,061.93 | 1,719,833,029.78 | 1,097,953,438.31 |
| 二、营业总成本 | 696,878,783.64 | 3,189,186,995.42 | 2,268,418,316.44 | 1,547,735,633.21 |
| 营业成本 | 116,956,477.99 | 413,540,499.77 | 270,593,449.58 | 175,019,080.53 |
| 税金及附加 | 5,584,048.63 | 16,351,262.08 | 12,367,642.39 | 7,942,580.41 |
| 销售费用 | 274,848,582.09 | 1,111,444,227.11 | 822,658,892.95 | 525,781,321.35 |
| 管理费用 | 80,418,546.93 | 364,275,477.75 | 215,621,316.7 | 146,312,149.24 |
| 研发费用 | 209,857,972.92 | 1,218,748,679.23 | 890,583,907.36 | 647,216,234.3 |
| 财务费用 | 9,213,155.08 | 64,826,849.48 | 56,593,107.46 | 45,464,267.38 |
| 其中:利息费用 | 13,358,762.26 | 70,168,113.76 | 57,040,326.33 | 41,811,862.2 |
| 其中:利息收入 | 1,095,285.09 | 4,594,430.84 | 3,570,684.25 | 2,439,986.87 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 361,201,867.87 | 640,713,336.7 | 293,722.97 | 52,149.71 |
| 加:投资收益 | -372,552.04 | -4,437,364.84 | -4,686,557.89 | -4,433,931.62 |
| 资产处置收益 | 5,832.56 | -771,569.73 | 205,690.01 | 178,554.91 |
| 资产减值损失(新) | - | -1,953,331.57 | -9,781.42 | - |
| 信用减值损失(新) | 5,568,592.25 | -576,311.93 | -3,632,557.18 | 2,058,764.7 |
| 其他收益 | 4,430,866.97 | 27,767,046.95 | 19,145,615.59 | 10,772,516.6 |
| 四、营业利润 | 330,170,273.88 | 722,605,872.09 | -537,269,154.58 | -441,154,140.6 |
| 加:营业外收入 | 220,023.98 | 950,289.57 | 797,697.78 | 178,676.42 |
| 减:营业外支出 | 1,896,657.94 | 13,157,673.32 | 14,229,118.58 | 8,593,198.89 |
| 五、利润总额 | 328,493,639.92 | 710,398,488.34 | -550,700,575.38 | -449,568,663.07 |
| 减:所得税费用 | 486,535 | 748,691.2 | - | - |
| 六、净利润 | 328,007,104.92 | 709,649,797.14 | -550,700,575.38 | -449,568,663.07 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 328,007,104.92 | 709,649,797.14 | -550,700,575.38 | -449,568,663.07 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 328,007,104.92 | 709,649,797.14 | -550,700,575.38 | -449,568,663.07 |
| 扣除非经常损益后的净利润 | -34,991,024.8 | 67,675,464.67 | -545,244,239.68 | -445,517,539.67 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.58 | 1.29 | -1.01 | -0.83 |
| (二)稀释每股收益 | 0.58 | 1.29 | -1.01 | -0.83 |
| 八、其他综合收益 | 330,879.64 | 52,652,126.87 | 49,592,840.32 | 30,010,415.8 |
| 归属于母公司股东的其他综合收益 | 330,879.64 | 52,652,126.87 | 49,592,840.32 | 30,010,415.8 |
| 九、综合收益总额 | 328,337,984.56 | 762,301,924.01 | -501,107,735.06 | -419,558,247.27 |
| 归属于母公司股东的综合收益总额 | 328,337,984.56 | 762,301,924.01 | -501,107,735.06 | -419,558,247.27 |
| 公告日期 | 2026-04-29 | 2026-03-28 | 2025-10-31 | 2025-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |